Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives $14.00 Average Price Target from Analysts

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has earned a consensus recommendation of “Reduce” from the nine research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and eight have given a hold rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $14.00.

Several analysts have recently issued reports on the company. Piper Sandler downgraded Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price target for the company. in a research note on Thursday, January 8th. Clear Str downgraded Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 7th. UBS Group restated a “neutral” rating and issued a $14.00 price objective (down previously from $20.00) on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Oppenheimer downgraded Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 8th. Finally, Wells Fargo & Company restated an “equal weight” rating and issued a $14.00 price target on shares of Ventyx Biosciences in a research report on Thursday, January 8th.

Ventyx Biosciences Stock Up 0.1%

Shares of Ventyx Biosciences stock opened at $13.97 on Friday. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $25.00. The business has a fifty day simple moving average of $12.17 and a 200-day simple moving average of $7.66. The stock has a market cap of $1.00 billion, a PE ratio of -9.31 and a beta of 1.25.

Insider Transactions at Ventyx Biosciences

In other news, CEO Raju Mohan sold 47,345 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the sale, the chief executive officer owned 2,372,863 shares in the company, valued at $18,318,502.36. The trade was a 1.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John Nuss sold 12,675 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the sale, the insider owned 489,481 shares of the company’s stock, valued at $3,778,793.32. This represents a 2.52% decrease in their position. The SEC filing for this sale provides additional information. 14.49% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ventyx Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTYX. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ventyx Biosciences during the fourth quarter worth $31,000. Hudson Bay Capital Management LP bought a new stake in Ventyx Biosciences in the 2nd quarter valued at about $34,000. Engineers Gate Manager LP acquired a new stake in Ventyx Biosciences during the second quarter worth approximately $42,000. Persistent Asset Partners Ltd acquired a new stake in shares of Ventyx Biosciences during the 3rd quarter worth $51,000. Finally, Jump Financial LLC bought a new position in Ventyx Biosciences in the 2nd quarter valued at about $53,000. 97.88% of the stock is owned by institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.